secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2022-06-13T23:59:59+00:00
Accession:  0001193125-22-172958
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Silverback Therapeutics stockholders elect directors, ratify auditor at 2022 annual meeting
--------------------------------------------------------------------------------

- Andrew Powell and Peter Thompson were elected Class II directors to serve until 2025 annual meeting.
- Ernst & Young LLP was ratified as independent auditor for fiscal year ending Dec 31, 2022 with 99.8% of votes in favor.
- Approximately 35.1 million shares were outstanding and entitled to vote as of April 11, 2022 record date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312522172958/0001193125-22-172958-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312522172958/d352185d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-172958

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer